<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03992430</url>
  </required_header>
  <id_info>
    <org_study_id>4658-402</org_study_id>
    <nct_id>NCT03992430</nct_id>
  </id_info>
  <brief_title>A Study to Compare Safety and Efficacy of a High Dose of Eteplirsen in Duchenne Muscular Dystrophy (DMD) Patients (MIS51ON)</brief_title>
  <official_title>A Randomized, Double-Blind, Dose Finding and Comparison Study of the Safety and Efficacy of a High Dose of Eteplirsen, Preceded by an Open-label Dose Escalation, in Patients With Duchenne Muscular Dystrophy With Deletion Mutations Amenable to Exon 51 Skipping</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sarepta Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sarepta Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be comprised of 2 parts: Part 1 will be conducted to evaluate the safety and
      tolerability of two doses (high dose level 1 and high dose level 2) of eteplirsen in
      approximately 8 patients; Part 2 will be conducted for the selection of a high dose (high
      dose level 1 vs high dose level 2) (dose finding phase), and its comparison with the 30 mg/kg
      dose of eteplirsen (dose comparison phase), in approximately 144 DMD patients with
      genetically confirmed deletion mutations amenable to treatment by skipping exon 51.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">January 2020</start_date>
  <completion_date type="Anticipated">October 2024</completion_date>
  <primary_completion_date type="Anticipated">October 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Part 1 is open-label, dose escalation; Part 2 is double-blind, dose finding and dose comparison</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Part 1 and Part 2 (Dose Finding): Incidences of Adverse Events (AEs)</measure>
    <time_frame>Baseline up to Week 148</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2 (Dose Finding): Dystrophin Expression in Biopsied Muscle Tissue</measure>
    <time_frame>Up to Week 48</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2 (Dose Finding): Pharmacokinetic (PK) Plasma Concentration of Eteplirsen</measure>
    <time_frame>Multiple timepoints up to Week 48</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2 (Dose Finding): Tissue Concentration of Eteplirsen From Biopsied Muscle Tissue</measure>
    <time_frame>Up to Week 48</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2 (Dose Comparison): Change From Baseline in the North Star Ambulatory Assessment (NSAA) Total Score</measure>
    <time_frame>Baseline, Week 144</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part 2 (Dose Comparison): Change From Baseline in the Total Distance Walked During 6-Minute Walk Test (6MWT)</measure>
    <time_frame>Baseline up to Week 144</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2 (Dose Comparison): Change From Baseline in Time to Complete Walk/run, Stairs and Time to Rise</measure>
    <time_frame>Baseline up to Week 144</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2 (Dose Comparison): Annual Rate in Decline of Forced Vital Capacity Percent Predicted (FVC%p)</measure>
    <time_frame>Up to Week 144</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2 (Dose Comparison): Time to Loss of Ambulation (LOA)</measure>
    <time_frame>Baseline up to Week 144</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2 (Dose Comparison): Change From Baseline in Skeletal Muscle Dystrophin Expression</measure>
    <time_frame>Baseline and Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2 (Dose Comparison): Incidence of Adverse Events (AEs)</measure>
    <time_frame>Baseline up to Week 144</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">152</enrollment>
  <condition>Muscular Dystrophy, Duchenne</condition>
  <arm_group>
    <arm_group_label>Part 1: Eteplirsen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive high dose level 1 of eteplirsen once weekly for at least 4 weeks, followed by high dose level 2 of eteplirsen once weekly for at least 4 weeks. Patients will continue treatment with the selected high dose as a distinct cohort for up to 144 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Eteplirsen 30 mg/kg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive eteplirsen 30 mg/kg once weekly for up to 144 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Eteplirsen-High Dose Level 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive high dose level 1 of eteplirsen once weekly before the selection of high dose occurs and then the selected high dose once weekly for up to 144 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Eteplirsen-High Dose Level 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive high dose level 2 of eteplirsen once weekly before the selection of high dose occurs and then the selected high dose once weekly for up to 144 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eteplirsen</intervention_name>
    <description>Solution for intravenous (IV) infusion.</description>
    <arm_group_label>Part 1: Eteplirsen</arm_group_label>
    <arm_group_label>Part 2: Eteplirsen 30 mg/kg</arm_group_label>
    <arm_group_label>Part 2: Eteplirsen-High Dose Level 1</arm_group_label>
    <arm_group_label>Part 2: Eteplirsen-High Dose Level 2</arm_group_label>
    <other_name>AVI-4658</other_name>
    <other_name>EXONDYS 51</other_name>
    <other_name>EXONDYS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Be a male with an established clinical diagnosis of DMD and an out-of-frame deletion
             mutation of the DMD gene amenable to exon 51 skipping.

          -  Have achieved a mean 6-minute walk test (6MWT) distance of greater than equal to (&gt;=)
             300 and less than equal to (&lt;=) 450 meters.

          -  Have intact right and left biceps muscles or an alternative upper arm muscle group.

          -  Have been on a stable dose or dose equivalent of oral corticosteroids for at least 24
             weeks prior to randomization.

          -  Have stable pulmonary function (forced vital capacity &gt;= 50 percent (%) of predicted
             and no requirement for nocturnal ventilation).

        Exclusion Criteria:

          -  Use of any pharmacologic treatment (other than corticosteroids) within 12 weeks prior
             to randomization.

          -  Current or previous treatment with gene therapy or any other experimental
             pharmacologic treatment for DMD; some exceptions apply.

          -  Previous treatment with drisapersen, ezutromid, or domagrozumab in the last 24 weeks
             prior to study enrollment.

          -  Major surgery within 3 months prior to randomization.

          -  Presence of any other significant neuromuscular or genetic disease other than DMD.

          -  Presence of other clinically significant illness.

          -  Has evidence of cardiomyopathy, as defined by left ventricular ejection fraction less
             than (&lt;) 50% on the screening Echocardiogram or QTcF &gt;= 450 millisecond based on the
             screening ECGs.

        Other inclusion/exclusion criteria apply.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>7 Years</minimum_age>
    <maximum_age>13 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Sarepta Therapeutics, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Medical Information</last_name>
    <phone>+1 888-727-3782</phone>
    <email>clinicaltrials@sarepta.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Children's Hospital - London Health Sciences Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5W9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Jayne</last_name>
      <phone>519-685-8500</phone>
      <phone_ext>56193</phone_ext>
      <email>Michelle.Jayne@lhsc.on.ca</email>
    </contact>
    <investigator>
      <last_name>Craig Campbell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Eastern Ontario</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rosa Ramos</last_name>
      <email>rramos@cheo.on.ca</email>
    </contact>
    <investigator>
      <last_name>Hugh McMillan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>June 18, 2019</study_first_submitted>
  <study_first_submitted_qc>June 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 20, 2019</study_first_posted>
  <last_update_submitted>January 16, 2020</last_update_submitted>
  <last_update_submitted_qc>January 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Duchenne muscular dystrophy</keyword>
  <keyword>Exon Skipping</keyword>
  <keyword>Exon 51</keyword>
  <keyword>North Star Ambulatory Assessment</keyword>
  <keyword>Ambulatory</keyword>
  <keyword>DMD</keyword>
  <keyword>Pediatric</keyword>
  <keyword>Duchenne</keyword>
  <keyword>EXONDYS</keyword>
  <keyword>MIS51ON</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscular Dystrophies</mesh_term>
    <mesh_term>Muscular Dystrophy, Duchenne</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

